Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

The European Commission has approved a fixed dose combination of Roche’s antibody blockbusters Herceptin and Perjeta under the new brand name Phesgo. ... The new combination treatment, containing Herceptin  (trastuzumab) and Perjeta (pertuzumab) with

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug The drug presents a new challenge to Roche’s dominant position in the HER2-positive breast cancer market, which includes a trio of targeted treatments – Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla ... The FDA approval and EMA

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report It has entered into a market dominated by Herceptin and other HER2-targeted therapies such as Perjeta and Tykerb.

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA Final decision due by 18 October. A fixed-dose combination of Roche’s HER2 drugs Herceptin and Perjeta has started a review at the US Food and Drug Administration (FDA), with ... Perjeta has been growing strongly – rising a third to $2.8bn last year

Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle Genetics wins FDA priority review for oral HER2 drug Herceptin plus Xeloda is a standard treatment regimen for HER2-positive breast cancer, in patients previously treated with Herceptin and Roche’s other HER-2 targeting drugs Perjeta (pertuzumab) and Kadcyla

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...